Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cytogen ratchets down

Cytogen ratchets down Cytogen Inc. announced a major cutback in research and staff, in response to both slow sales of its OncoScint imaging agent and the current health care environment.

Almost everything not in Phase III or beyond is being put in mothballs, President Thomas McKearn told BioCentury. That includes four imaging agents (OncoScint Colorectal CEA, OncoScint NSC Lung, OncoScint Breast and OncoScint Bladder) and

Read the full 660 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE